# EDGAR Filing Document

**Accession Number:** 0001687078
**File Stem:** 0001438934-25-000683
**Filing Date:** 2025-8
**Character Count:** 69648
**Document Hash:** 3146bae9a6c006daf3617e72f74ad3d9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001438934-25-000683.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0001438934-25-000683

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250812

**EFFECTIVENESS DATE**: 20250812

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MPM BioImpact LLC
- **CENTRAL INDEX KEY:** 0001687078

**ORGANIZATION NAME:**
- **EIN:** 364818254
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-20107
- **FILM NUMBER:** 251204828

**BUSINESS ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 6174259200

**MAIL ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioImpact Capital LLC
- **DATE OF NAME CHANGE:** 20210831

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MPM Oncology Impact Management LP
- **DATE OF NAME CHANGE:** 20161007

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001687078

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** MPM BioImpact LLC

**Address:** 399 Boylston Street, Boston, MA 02116

**Telephone number:** 6174259203

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-20107

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [ ] No

- [x] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 1

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                  | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                          | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   | SHARES VOTED FOR OR AGAINST MANAGEMENT   | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|:---|:---|:---|
| ALKERMES PLC                    | G01767105 | 05/21/2025     | To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |         181080 |                0 | FOR         | 181080                                   | FOR                         |  |
| ALX ONCOLOGY HOLDINGS INC       | 00166B105 | 06/11/2025     | Advisory vote to approve named executive officer compensation.                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |          10318 |                0 | FOR         | 10318                                    | FOR                         |  |
| AVADEL PHARMACEUTICALS PLC      | G29687103 | 07/30/2024     | To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company.                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         674489 |                0 | FOR         | 674489                                   | FOR                         |  |
| AVIDITY BIOSCIENCES, INC.       | 05370A108 | 06/10/2025     | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.                           | SECTION 14A SAY-ON-PAY VOTES |         296658 |                0 | FOR         | 296658                                   | FOR                         |  |
| BLUEPRINT MEDICINES CORPORATION | 09627Y109 | 06/18/2025     | Approval of a non-binding advisory vote on the compensation paid to our named executive officers.                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |          53932 |                0 | FOR         | 53932                                    | FOR                         |  |
| CARTESIAN THERAPEUTICS, INC.    | 816212302 | 06/13/2025     | To approve, on a non-binding and advisory basis, a resolution approving the compensation of Cartesian Therapeutics, Inc.'s named executive officers, as described in the accompanying proxy statement under "Executive and Director Compensation."        | SECTION 14A SAY-ON-PAY VOTES |          54298 |                0 | FOR         | 54298                                    | FOR                         |  |
| CRINETICS PHARMACEUTICALS INC.  | 22663K107 | 06/11/2025     | To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.                  | SECTION 14A SAY-ON-PAY VOTES |         309697 |                0 | FOR         | 309697                                   | FOR                         |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS MAKING UP THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND, PAID DURING THE FINANCIAL YEAR 2024 OR AWARDED FOR THE SAME FINANCIAL YEAR TO MR. MICHEL DE ROSEN, CHAIRMAN OF THE BOARD OF DIRECTORS | SECTION 14A SAY-ON-PAY VOTES |              6 |                0 | FOR         | 6                                        | FOR                         |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS MAKING UP THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND, PAID DURING THE FINANCIAL YEAR 2024 OR AWARDED FOR THE SAME FINANCIAL YEAR TO MR. DANIEL TASSE, CHIEF EXECUTIVE OFFICER               | SECTION 14A SAY-ON-PAY VOTES |              6 |                0 | FOR         | 6                                        | FOR                         |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | CONSULTATIVE OPINION ON THE REMUNERATION OF EXECUTIVE MANAGERS 'NAMED EXECUTIVE OFFICERS' OTHER THAN THE CHIEF EXECUTIVE OFFICER                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |              6 |                0 | FOR         | 6                                        | FOR                         |  |
| EDGEWISE THERAPEUTICS INC       | 28036F105 | 06/13/2025     | Conduct an advisory vote on the compensation of our named executive officers.                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         896508 |                0 | FOR         | 896508                                   | FOR                         |  |
| EDGEWISE THERAPEUTICS INC       | 28036F105 | 06/13/2025     | Conduct an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |         896508 |                0 | 1 YEAR      | 896508                                   | FOR                         |  |
| GUARDANT HEALTH, INC.           | 40131M109 | 06/18/2025     | Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |         337462 |                0 | FOR         | 337462                                   | FOR                         |  |
| IOVANCE BIOTHERAPEUTICS, INC.   | 462260100 | 06/10/2025     | To approve, by non-binding advisory vote, the compensation of our named executive officers.                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |         241217 |                0 | FOR         | 241217                                   | FOR                         |  |
| JANUX THERAPEUTICS, INC.        | 47103J105 | 06/11/2025     | Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |         221266 |                0 | FOR         | 221266                                   | FOR                         |  |
| JANUX THERAPEUTICS, INC.        | 47103J105 | 06/11/2025     | Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |         221266 |                0 | 1 YEAR      | 221266                                   | FOR                         |  |
| KALVISTA PHARMACEUTICALS, INC.  | 483497103 | 10/03/2024     | Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |         607787 |                0 | FOR         | 607787                                   | FOR                         |  |
| LANTHEUS HOLDINGS, INC.         | 516544103 | 05/01/2025     | The approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         126168 |                0 | FOR         | 126168                                   | FOR                         |  |
| MADRIGAL PHARMACEUTICALS INC.   | 558868105 | 06/20/2025     | Advisory vote to approve executive compensation                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |           4181 |                0 | FOR         | 4181                                     | FOR                         |  |
| MADRIGAL PHARMACEUTICALS INC.   | 558868105 | 06/20/2025     | Advisory vote to approve the frequency of future advisory votes to approve executive compensation                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |           4181 |                0 | 1 YEAR      | 4181                                     | FOR                         |  |
| MOONLAKE IMMUNOTHERAPEUTICS     | 61559X104 | 06/05/2025     | Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |         169821 |                0 | FOR         | 169821                                   | FOR                         |  |
| NATERA, INC.                    | 632307104 | 06/12/2025     | To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |          76236 |                0 | FOR         | 76236                                    | FOR                         |  |
| NUVATION BIO INC.               | 67080N101 | 05/21/2025     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |        1592829 |                0 | FOR         | 1592829                                  | FOR                         |  |
| OLEMA PHARMACEUTICALS, INC.     | 68062P106 | 06/10/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |         645569 |                0 | FOR         | 645569                                   | FOR                         |  |
| PTC THERAPEUTICS, INC.          | 69366J200 | 06/17/2025     | Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |         120126 |                0 | FOR         | 120126                                   | FOR                         |  |
| RELAY THERAPEUTICS, INC.        | 75943R102 | 06/06/2025     | To consider and act upon an advisory vote on the compensation of our named executive officers.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |         714635 |                0 | FOR         | 714635                                   | FOR                         |  |
| REVOLUTION MEDICINES, INC.      | 76155X100 | 06/26/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").      | SECTION 14A SAY-ON-PAY VOTES |          73429 |                0 | FOR         | 73429                                    | FOR                         |  |
| ROCKET PHARMACEUTICALS, INC.    | 77313F106 | 06/18/2025     | Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers.                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |         619591 |                0 | FOR         | 619591                                   | FOR                         |  |
| SOLID BIOSCIENCES INC.          | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |         712633 |                0 | FOR         | 712633                                   | FOR                         |  |
| STOKE THERAPEUTICS, INC.        | 86150R107 | 06/03/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         230877 |                0 | FOR         | 230877                                   | FOR                         |  |
| STOKE THERAPEUTICS, INC.        | 86150R107 | 06/03/2025     | To indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes to approve the compensation of the Company's named executive officers.                                                                                    | SECTION 14A SAY-ON-PAY VOTES |         230877 |                0 | 1 YEAR      | 230877                                   | FOR                         |  |
| TREVI THERAPEUTICS INC          | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |        1701225 |                0 | FOR         | 1701225                                  | FOR                         |  |
| TREVI THERAPEUTICS INC          | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers.                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |        1701225 |                0 | 1 YEAR      | 1701225                                  | FOR                         |  |
| TWIST BIOSCIENCE CORPORATION    | 90184D100 | 02/05/2025     | To adopt, on an advisory basis, a resolution approving the compensation of the Company's Named Executive Officers, as described in the Proxy Statement under "Executive Compensation."                                                                    | SECTION 14A SAY-ON-PAY VOTES |         152309 |                0 | FOR         | 152309                                   | FOR                         |  |
| ULTRAGENYX PHARMACEUTICAL INC.  | 90400D108 | 05/15/2025     | Advisory (non-binding) vote to approve the compensation of our named executive officers.                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |         194481 |                0 | FOR         | 194481                                   | FOR                         |  |
| VERA THERAPEUTICS, INC.         | 92337R101 | 05/14/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |         205022 |                0 | FOR         | 205022                                   | FOR                         |  |
| VERA THERAPEUTICS, INC.         | 92337R101 | 05/14/2025     | To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |         205022 |                0 | 1 YEAR      | 205022                                   | FOR                         |  |
| XENON PHARMACEUTICALS INC       | 98420N105 | 06/04/2025     | To approve, on an advisory basis, the compensation of the Corporation's named executive officers.                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |         153517 |                0 | FOR         | 153517                                   | FOR                         |  |
| ZAI LAB LTD                     | 98887Q104 | 06/18/2025     | An ordinary resolution to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |         307631 |                0 | FOR         | 307631                                   | FOR                         |  |
| ALKERMES PLC                    | G01767105 | 05/21/2025     | To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| AVIDITY BIOSCIENCES, INC.       | 05370A108 | 06/10/2025     | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.                           | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| BLUEPRINT MEDICINES CORPORATION | 09627Y109 | 06/18/2025     | Approval of a non-binding advisory vote on the compensation paid to our named executive officers.                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| CARTESIAN THERAPEUTICS, INC.    | 816212302 | 06/13/2025     | To approve, on a non-binding and advisory basis, a resolution approving the compensation of Cartesian Therapeutics, Inc.'s named executive officers, as described in the accompanying proxy statement under "Executive and Director Compensation."        | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| CRINETICS PHARMACEUTICALS INC.  | 22663K107 | 06/11/2025     | To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.                  | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS MAKING UP THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND, PAID DURING THE FINANCIAL YEAR 2024 OR AWARDED FOR THE SAME FINANCIAL YEAR TO MR. MICHEL DE ROSEN, CHAIRMAN OF THE BOARD OF DIRECTORS | SECTION 14A SAY-ON-PAY VOTES |              1 |                0 | FOR         | 1                                        | FOR                         |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS MAKING UP THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND, PAID DURING THE FINANCIAL YEAR 2024 OR AWARDED FOR THE SAME FINANCIAL YEAR TO MR. DANIEL TASSE, CHIEF EXECUTIVE OFFICER               | SECTION 14A SAY-ON-PAY VOTES |              1 |                0 | FOR         | 1                                        | FOR                         |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | CONSULTATIVE OPINION ON THE REMUNERATION OF EXECUTIVE MANAGERS 'NAMED EXECUTIVE OFFICERS' OTHER THAN THE CHIEF EXECUTIVE OFFICER                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |              1 |                0 | FOR         | 1                                        | FOR                         |  |
| EDGEWISE THERAPEUTICS INC       | 28036F105 | 06/13/2025     | Conduct an advisory vote on the compensation of our named executive officers.                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| EDGEWISE THERAPEUTICS INC       | 28036F105 | 06/13/2025     | Conduct an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| IOVANCE BIOTHERAPEUTICS, INC.   | 462260100 | 06/10/2025     | To approve, by non-binding advisory vote, the compensation of our named executive officers.                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| JANUX THERAPEUTICS, INC.        | 47103J105 | 06/11/2025     | Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| JANUX THERAPEUTICS, INC.        | 47103J105 | 06/11/2025     | Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| KALVISTA PHARMACEUTICALS, INC.  | 483497103 | 10/03/2024     | Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |         115545 |                0 | FOR         | 115545                                   | FOR                         |  |
| MADRIGAL PHARMACEUTICALS INC.   | 558868105 | 06/20/2025     | Advisory vote to approve executive compensation                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| MADRIGAL PHARMACEUTICALS INC.   | 558868105 | 06/20/2025     | Advisory vote to approve the frequency of future advisory votes to approve executive compensation                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| MOONLAKE IMMUNOTHERAPEUTICS     | 61559X104 | 06/05/2025     | Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| NUVATION BIO INC.               | 67080N101 | 05/21/2025     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| OLEMA PHARMACEUTICALS, INC.     | 68062P106 | 06/10/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| PTC THERAPEUTICS, INC.          | 69366J200 | 06/17/2025     | Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| RELAY THERAPEUTICS, INC.        | 75943R102 | 06/06/2025     | To consider and act upon an advisory vote on the compensation of our named executive officers.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| REVOLUTION MEDICINES, INC.      | 76155X100 | 06/26/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").      | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| ROCKET PHARMACEUTICALS, INC.    | 77313F106 | 06/18/2025     | Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers.                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| SOLID BIOSCIENCES INC.          | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| STOKE THERAPEUTICS, INC.        | 86150R107 | 06/03/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| STOKE THERAPEUTICS, INC.        | 86150R107 | 06/03/2025     | To indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes to approve the compensation of the Company's named executive officers.                                                                                    | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| TREVI THERAPEUTICS INC          | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| TREVI THERAPEUTICS INC          | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers.                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| ULTRAGENYX PHARMACEUTICAL INC.  | 90400D108 | 05/15/2025     | Advisory (non-binding) vote to approve the compensation of our named executive officers.                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| VERA THERAPEUTICS, INC.         | 92337R101 | 05/14/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| VERA THERAPEUTICS, INC.         | 92337R101 | 05/14/2025     | To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| XENON PHARMACEUTICALS INC       | 98420N105 | 06/04/2025     | To approve, on an advisory basis, the compensation of the Corporation's named executive officers.                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| ZAI LAB LTD                     | 98887Q104 | 06/18/2025     | An ordinary resolution to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| ALKERMES PLC                    | G01767105 | 05/21/2025     | To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |          56273 |                0 | FOR         | 56273                                    | FOR                         |  |
| ALX ONCOLOGY HOLDINGS INC       | 00166B105 | 06/11/2025     | Advisory vote to approve named executive officer compensation.                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |          14978 |                0 | FOR         | 14978                                    | FOR                         |  |
| AVADEL PHARMACEUTICALS PLC      | G29687103 | 07/30/2024     | To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company.                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         208758 |                0 | FOR         | 208758                                   | FOR                         |  |
| AVIDITY BIOSCIENCES, INC.       | 05370A108 | 06/10/2025     | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.                           | SECTION 14A SAY-ON-PAY VOTES |          92475 |                0 | FOR         | 92475                                    | FOR                         |  |
| BLUEPRINT MEDICINES CORPORATION | 09627Y109 | 06/18/2025     | Approval of a non-binding advisory vote on the compensation paid to our named executive officers.                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |          16654 |                0 | FOR         | 16654                                    | FOR                         |  |
| CARTESIAN THERAPEUTICS, INC.    | 816212302 | 06/13/2025     | To approve, on a non-binding and advisory basis, a resolution approving the compensation of Cartesian Therapeutics, Inc.'s named executive officers, as described in the accompanying proxy statement under "Executive and Director Compensation."        | SECTION 14A SAY-ON-PAY VOTES |             17 |                0 | FOR         | 17                                       | FOR                         |  |
| CRINETICS PHARMACEUTICALS INC.  | 22663K107 | 06/11/2025     | To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.                  | SECTION 14A SAY-ON-PAY VOTES |          96539 |                0 | FOR         | 96539                                    | FOR                         |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS MAKING UP THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND, PAID DURING THE FINANCIAL YEAR 2024 OR AWARDED FOR THE SAME FINANCIAL YEAR TO MR. MICHEL DE ROSEN, CHAIRMAN OF THE BOARD OF DIRECTORS | SECTION 14A SAY-ON-PAY VOTES |              4 |                0 | FOR         | 4                                        | FOR                         |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS MAKING UP THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND, PAID DURING THE FINANCIAL YEAR 2024 OR AWARDED FOR THE SAME FINANCIAL YEAR TO MR. DANIEL TASSE, CHIEF EXECUTIVE OFFICER               | SECTION 14A SAY-ON-PAY VOTES |              4 |                0 | FOR         | 4                                        | FOR                         |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | CONSULTATIVE OPINION ON THE REMUNERATION OF EXECUTIVE MANAGERS 'NAMED EXECUTIVE OFFICERS' OTHER THAN THE CHIEF EXECUTIVE OFFICER                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |              4 |                0 | FOR         | 4                                        | FOR                         |  |
| EDGEWISE THERAPEUTICS INC       | 28036F105 | 06/13/2025     | Conduct an advisory vote on the compensation of our named executive officers.                                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         275131 |                0 | FOR         | 275131                                   | FOR                         |  |
| EDGEWISE THERAPEUTICS INC       | 28036F105 | 06/13/2025     | Conduct an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |         275131 |                0 | 1 YEAR      | 275131                                   | FOR                         |  |
| GUARDANT HEALTH, INC.           | 40131M109 | 06/18/2025     | Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |         105194 |                0 | FOR         | 105194                                   | FOR                         |  |
| IOVANCE BIOTHERAPEUTICS, INC.   | 462260100 | 06/10/2025     | To approve, by non-binding advisory vote, the compensation of our named executive officers.                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |          75484 |                0 | FOR         | 75484                                    | FOR                         |  |
| JANUX THERAPEUTICS, INC.        | 47103J105 | 06/11/2025     | Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |          68727 |                0 | FOR         | 68727                                    | FOR                         |  |
| JANUX THERAPEUTICS, INC.        | 47103J105 | 06/11/2025     | Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |          68727 |                0 | 1 YEAR      | 68727                                    | FOR                         |  |
| KALVISTA PHARMACEUTICALS, INC.  | 483497103 | 10/03/2024     | Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |         182292 |                0 | FOR         | 182292                                   | FOR                         |  |
| LANTHEUS HOLDINGS, INC.         | 516544103 | 05/01/2025     | The approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |          39481 |                0 | FOR         | 39481                                    | FOR                         |  |
| MADRIGAL PHARMACEUTICALS INC.   | 558868105 | 06/20/2025     | Advisory vote to approve executive compensation                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |            137 |                0 | FOR         | 137                                      | FOR                         |  |
| MADRIGAL PHARMACEUTICALS INC.   | 558868105 | 06/20/2025     | Advisory vote to approve the frequency of future advisory votes to approve executive compensation                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |            137 |                0 | 1 YEAR      | 137                                      | FOR                         |  |
| MOONLAKE IMMUNOTHERAPEUTICS     | 61559X104 | 06/05/2025     | Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |          52912 |                0 | FOR         | 52912                                    | FOR                         |  |
| NATERA, INC.                    | 632307104 | 06/12/2025     | To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |          23764 |                0 | FOR         | 23764                                    | FOR                         |  |
| NUVATION BIO INC.               | 67080N101 | 05/21/2025     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |         498578 |                0 | FOR         | 498578                                   | FOR                         |  |
| OLEMA PHARMACEUTICALS, INC.     | 68062P106 | 06/10/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |         202017 |                0 | FOR         | 202017                                   | FOR                         |  |
| PTC THERAPEUTICS, INC.          | 69366J200 | 06/17/2025     | Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |          37250 |                0 | FOR         | 37250                                    | FOR                         |  |
| RELAY THERAPEUTICS, INC.        | 75943R102 | 06/06/2025     | To consider and act upon an advisory vote on the compensation of our named executive officers.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |         223631 |                0 | FOR         | 223631                                   | FOR                         |  |
| REVOLUTION MEDICINES, INC.      | 76155X100 | 06/26/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").      | SECTION 14A SAY-ON-PAY VOTES |          22978 |                0 | FOR         | 22978                                    | FOR                         |  |
| ROCKET PHARMACEUTICALS, INC.    | 77313F106 | 06/18/2025     | Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers.                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |         192645 |                0 | FOR         | 192645                                   | FOR                         |  |
| SOLID BIOSCIENCES INC.          | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |         221501 |                0 | FOR         | 221501                                   | FOR                         |  |
| STOKE THERAPEUTICS, INC.        | 86150R107 | 06/03/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |          72248 |                0 | FOR         | 72248                                    | FOR                         |  |
| STOKE THERAPEUTICS, INC.        | 86150R107 | 06/03/2025     | To indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes to approve the compensation of the Company's named executive officers.                                                                                    | SECTION 14A SAY-ON-PAY VOTES |          72248 |                0 | 1 YEAR      | 72248                                    | FOR                         |  |
| TREVI THERAPEUTICS INC          | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |         527661 |                0 | FOR         | 527661                                   | FOR                         |  |
| TREVI THERAPEUTICS INC          | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers.                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |         527661 |                0 | 1 YEAR      | 527661                                   | FOR                         |  |
| TWIST BIOSCIENCE CORPORATION    | 90184D100 | 02/05/2025     | To adopt, on an advisory basis, a resolution approving the compensation of the Company's Named Executive Officers, as described in the Proxy Statement under "Executive Compensation."                                                                    | SECTION 14A SAY-ON-PAY VOTES |          11242 |                0 | FOR         | 11242                                    | FOR                         |  |
| ULTRAGENYX PHARMACEUTICAL INC.  | 90400D108 | 05/15/2025     | Advisory (non-binding) vote to approve the compensation of our named executive officers.                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |          60624 |                0 | FOR         | 60624                                    | FOR                         |  |
| VERA THERAPEUTICS, INC.         | 92337R101 | 05/14/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |          63619 |                0 | FOR         | 63619                                    | FOR                         |  |
| VERA THERAPEUTICS, INC.         | 92337R101 | 05/14/2025     | To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |          63619 |                0 | 1 YEAR      | 63619                                    | FOR                         |  |
| XENON PHARMACEUTICALS INC       | 98420N105 | 06/04/2025     | To approve, on an advisory basis, the compensation of the Corporation's named executive officers.                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |          47946 |                0 | FOR         | 47946                                    | FOR                         |  |
| ZAI LAB LTD                     | 98887Q104 | 06/18/2025     | An ordinary resolution to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |          67632 |                0 | FOR         | 67632                                    | FOR                         |  |
| AVIDITY BIOSCIENCES, INC.       | 05370A108 | 06/10/2025     | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.                           | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| CARTESIAN THERAPEUTICS, INC.    | 816212302 | 06/13/2025     | To approve, on a non-binding and advisory basis, a resolution approving the compensation of Cartesian Therapeutics, Inc.'s named executive officers, as described in the accompanying proxy statement under "Executive and Director Compensation."        | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| IOVANCE BIOTHERAPEUTICS, INC.   | 462260100 | 06/10/2025     | To approve, by non-binding advisory vote, the compensation of our named executive officers.                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| LANTHEUS HOLDINGS, INC.         | 516544103 | 05/01/2025     | The approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| PTC THERAPEUTICS, INC.          | 69366J200 | 06/17/2025     | Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| ROCKET PHARMACEUTICALS, INC.    | 77313F106 | 06/18/2025     | Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers.                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| SOLID BIOSCIENCES INC.          | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| STOKE THERAPEUTICS, INC.        | 86150R107 | 06/03/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| STOKE THERAPEUTICS, INC.        | 86150R107 | 06/03/2025     | To indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes to approve the compensation of the Company's named executive officers.                                                                                    | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| ALX ONCOLOGY HOLDINGS INC       | 00166B105 | 06/11/2025     | Advisory vote to approve named executive officer compensation.                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |          75969 |                0 | FOR         | 75969                                    | FOR                         |  |
| AVIDITY BIOSCIENCES, INC.       | 05370A108 | 06/10/2025     | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.                           | SECTION 14A SAY-ON-PAY VOTES |          99869 |                0 | FOR         | 99869                                    | FOR                         |  |
| BLUEPRINT MEDICINES CORPORATION | 09627Y109 | 06/18/2025     | Approval of a non-binding advisory vote on the compensation paid to our named executive officers.                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |          33537 |                0 | FOR         | 33537                                    | FOR                         |  |
| CARTESIAN THERAPEUTICS, INC.    | 816212302 | 06/13/2025     | To approve, on a non-binding and advisory basis, a resolution approving the compensation of Cartesian Therapeutics, Inc.'s named executive officers, as described in the accompanying proxy statement under "Executive and Director Compensation."        | SECTION 14A SAY-ON-PAY VOTES |          18253 |                0 | FOR         | 18253                                    | FOR                         |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS MAKING UP THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND, PAID DURING THE FINANCIAL YEAR 2024 OR AWARDED FOR THE SAME FINANCIAL YEAR TO MR. MICHEL DE ROSEN, CHAIRMAN OF THE BOARD OF DIRECTORS | SECTION 14A SAY-ON-PAY VOTES |              1 |                0 | FOR         | 1                                        | FOR                         |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL ELEMENTS MAKING UP THE TOTAL REMUNERATION AND BENEFITS OF ANY KIND, PAID DURING THE FINANCIAL YEAR 2024 OR AWARDED FOR THE SAME FINANCIAL YEAR TO MR. DANIEL TASSE, CHIEF EXECUTIVE OFFICER               | SECTION 14A SAY-ON-PAY VOTES |              1 |                0 | FOR         | 1                                        | FOR                         |  |
| DBV TECHNOLOGIES SA             | F2927N109 | 06/11/2025     | CONSULTATIVE OPINION ON THE REMUNERATION OF EXECUTIVE MANAGERS 'NAMED EXECUTIVE OFFICERS' OTHER THAN THE CHIEF EXECUTIVE OFFICER                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |              1 |                0 | FOR         | 1                                        | FOR                         |  |
| IOVANCE BIOTHERAPEUTICS, INC.   | 462260100 | 06/10/2025     | To approve, by non-binding advisory vote, the compensation of our named executive officers.                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |         330791 |                0 | FOR         | 330791                                   | FOR                         |  |
| JANUX THERAPEUTICS, INC.        | 47103J105 | 06/11/2025     | Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |         129242 |                0 | FOR         | 129242                                   | FOR                         |  |
| JANUX THERAPEUTICS, INC.        | 47103J105 | 06/11/2025     | Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |         129242 |                0 | 1 YEAR      | 129242                                   | FOR                         |  |
| LANTHEUS HOLDINGS, INC.         | 516544103 | 05/01/2025     | The approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |          58500 |                0 | FOR         | 58500                                    | FOR                         |  |
| NUVATION BIO INC.               | 67080N101 | 05/21/2025     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |        1407715 |                0 | FOR         | 1407715                                  | FOR                         |  |
| OLEMA PHARMACEUTICALS, INC.     | 68062P106 | 06/10/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |        1602696 |                0 | FOR         | 1602696                                  | FOR                         |  |
| PTC THERAPEUTICS, INC.          | 69366J200 | 06/17/2025     | Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |         170949 |                0 | FOR         | 170949                                   | FOR                         |  |
| RELAY THERAPEUTICS, INC.        | 75943R102 | 06/06/2025     | To consider and act upon an advisory vote on the compensation of our named executive officers.                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |         832017 |                0 | FOR         | 832017                                   | FOR                         |  |
| REVOLUTION MEDICINES, INC.      | 76155X100 | 06/26/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").      | SECTION 14A SAY-ON-PAY VOTES |         166666 |                0 | FOR         | 166666                                   | FOR                         |  |
| ROCKET PHARMACEUTICALS, INC.    | 77313F106 | 06/18/2025     | Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers.                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |         334424 |                0 | FOR         | 334424                                   | FOR                         |  |
| SOLID BIOSCIENCES INC.          | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |         251505 |                0 | FOR         | 251505                                   | FOR                         |  |
| STOKE THERAPEUTICS, INC.        | 86150R107 | 06/03/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         212577 |                0 | FOR         | 212577                                   | FOR                         |  |
| STOKE THERAPEUTICS, INC.        | 86150R107 | 06/03/2025     | To indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes to approve the compensation of the Company's named executive officers.                                                                                    | SECTION 14A SAY-ON-PAY VOTES |         212577 |                0 | 1 YEAR      | 212577                                   | FOR                         |  |
| ZAI LAB LTD                     | 98887Q104 | 06/18/2025     | An ordinary resolution to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |         197786 |                0 | FOR         | 197786                                   | FOR                         |  |
| ADAPTIMMUNE THERAPEUTICS PLC    | 00653A107 | 05/29/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2024.                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |        4411821 |                0 | FOR         | 4411821                                  | FOR                         |  |
| ADAPTIMMUNE THERAPEUTICS PLC    | 00653A107 | 05/29/2025     | To approve, on a non-binding, advisory basis, the preferred frequency of future shareholder advisory votes on the compensation of the Company's named executive officers. (Advisory Resolution)                                                           | SECTION 14A SAY-ON-PAY VOTES |        4411821 |                0 | 1 YEAR      | 4411821                                  | FOR                         |  |
| CULLINAN THERAPEUTICS, INC.     | 230031106 | 06/12/2025     | Proposal to vote, on an advisory basis, to approve our named executive officer compensation.                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |        7648268 |                0 | FOR         | 7648268                                  | FOR                         |  |
| CULLINAN THERAPEUTICS, INC.     | 230031106 | 06/12/2025     | Proposal to vote, on an advisory basis, on the frequency of future advisory votes on our named executive officer compensation.                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |        7648268 |                0 | 1 YEAR      | 7648268                                  | FOR                         |  |
| REPARE THERAPEUTICS INC.        | 760273102 | 06/17/2025     | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement.                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |         569924 |                0 | FOR         | 569924                                   | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** MPM BioImpact LLC

**By (Signature):** Brendan Furey

**By (Printed Signature):** Brendan Furey

**By (Title):** Chief Compliance Officer

**Date:** 08/07/2025